Special Edition: Lp(a) & CV Risk

Over two decades ago, Lipoprotein(a)—or Lp(a)—was recognized as an emerging risk factor for cardiovascular disease. In this special edition of DOC Updates, Dr. Neil Skolnik explores our growing understanding of this cholesterol-carrying lipoprotein.

This special episode is sponsored with support from Lilly.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

EPISODE NOTES

Special Edition: Special Edition: Lp(a) & CV Risk

In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Michael Wilkinson, who goes over the history of Lp(a), the current guidelines, and the importance of screening.

This special episode is sponsored with support from Lilly.

Presented by:

-Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

-Michael Wilkinson, MD, Associate Professor of Medicine at University of California San Diego Health, and Director of the advanced lipid treatment program at UC San Diego Health, Board of Directors of the National Lipid Association and Associate editor of the American Journal of Preventive Cardiology

References:

-The American Heart Association PREVENT Online Calculator

-Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects – Circulation 2025; 151:400-415

-2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation Volume 153, Issue 17, 28 April 2026; Pages e1154-e1276

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(100)

Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D

To achieve optimal outcomes for patients, it is not only the individual efforts of clinicians that matter in achieving optimal outcomes for our patients. Having a system that supports and facilitates ...

17 Elo 33min

Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more!

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE...

10 Elo 35min

Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!

Welcome to the latest episode (August 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease...

10 Elo 32min

Special Edition: Hypertension Part I—Overview and Management

In the first episode of this special three-part series, Neil Skolnik speaks with Dr. Minesh Rajpal. Together, they provide an overview, discussing the assessment and management of high blood pressure....

6 Elo 33min

Special Edition: Highlights from the ADA's 2026 Scientific Sessions

In this special crossover episode, recorded live at the American Diabetes Association's Scientific Sessions in New Orleans, the hosts of the ADA's professional podcasts—DOC Updates, Diabetes Care "On ...

30 Heinä 44min

Special Edition: What's Next—Once-Weekly Insulins—Mechanisms and Practical Considerations

Continuing his exploration of once-weekly insulins, Neil Skolnik speaks with Aaron King, MD. Together, they cover the mechanisms, practical considerations, and the myriad benefits that this new therap...

17 Heinä 25min

Special Edition: What's Next—CKD in Type 1 Diabetes—An Urgent Need for Therapies

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available ...

7 Heinä 28min